Navigation Links
DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
Date:4/1/2008

EL SEGUNDO, Calif., April 1, 2008 /PRNewswire/ -- DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney failure and disease, today announced its former Chief Medical Officer (CMO) Charles J. McAllister, M.D. will retire effective April 1, 2008. Dr. McAllister stepped down as CMO in July 2007, and has since served as CMO emeritus in the Office of the CMO.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

"Charlie has provided 30 years of incredible service to kidney care patients and the broader kidney care community, as a practicing nephrologist, as a hospital chief of staff and as DaVita's chief medical officer," said DaVita CEO Kent Thiry. "The combination of his energy, his intellect, his sense of humor and his warm bedside manner is amazing."

Dr. McAllister served as CMO for DaVita(R) since 2000. During that time, his dedication to continuous improvement in the areas of physician performance management, national clinical measurement development, product evaluation and testing, and clinical compliance program implementation, among others, helped DaVita become a national leader in clinical outcomes. Dr. McAllister's efforts also helped shaped DaVita's community-like work environment, which has been broadly written about and is taught at many major business schools.

"Dr. McAllister really represents the life-force of the Physician Council at DaVita, serving as DaVita's physician beacon of outstanding and compassionate care for our most vulnerable patients," said John Robertson, M.D. "All of the physicians remaining with the Office of the Chief Medical Officer will continue to aspire to the same level of professionalism and integrity that Charlie single handedly inspired since the day he joined with DaVita."

Prior to serving as CMO for DaVita, Dr. McAllister served as vice president of medical affairs for Gambro and Vivra, respectively. He also spent more than 20 years as medical director of dialysis facilities in the Tampa Bay area, where as one of the first practicing local nephrologists, he created dialysis programs serving a community of more than one million people.

"Of my major accomplishments, I'm especially proud of being given the honor to work with many colleagues, nurses, dieticians and others -- I was able to learn from them all," said Dr. McAllister. "As I retire from my executive career, I plan on working in the not-for-profit sector with the disadvantaged and underserved. I'm actually looking forward to putting back on my white coat and stethoscope."

Dr. McAllister has accepted a part-time position as medical director with Bay Area Treatment Center in Pinellas Park, Fla., where he will work with individuals suffering from substance dependence.

The Office of the CMO replaced the position of DaVita CMO on July 1, 2007. Membership comprises John Robertson, M.D., David Van Wyck, M.D. and Robert Provenzano, M.D.; and Allen Nissenson, M.D. serves as Special Advisor to the Office of the CMO.

DaVita is a registered trademark of DaVita Inc. All other trademarks are the property of their respective owners.

About DaVita Inc.

DaVita Inc., a FORTUNE 500(R) company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita manages over 1,300 outpatient facilities and acute units in over 700 hospitals located in 43 states and the District of Columbia, serving approximately 107,000 patients. For more information, please visit http://www.davita.com.


'/>"/>
SOURCE DaVita Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NxStage Medical Announces Needle Supply Agreement with DaVita
2. DaVita to Present at UBS Best of Americas Conference
3. Human Pheromone Sciences Announces Quarterly and Full Year Results
4. Dragon Pharma announces 2007 full year financial results
5. Genaera Corporation Announces 2007 Financial Results
6. Genmab Announces Year End 2007 Financial Results
7. Immunosyn Corporation Announces 2007 Results, Files 10KSB
8. Elbit Imaging Ltd. Announces Results For Fiscal Year 2007
9. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
10. China Pharma Holdings, Inc. Announces Record 2007 Year End Results
11. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):